Cervical Cancer Screening
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLABOOZ alerts
Get alerted when Policy CPCPLABOOZ changes without checking for updates manually.
Monitor payer policy activity
Reimbursement and coverage criteria for cervical cancer screening tests (cytology and high-risk HPV) for Blue Cross Blue Shield - Oklahoma members; applies to providers submitting claims for individuals with a cervix.
Reimbursement criterion #5 revised to state: For individuals who are pooled hr-HPV positive, nucleic acid testing for high-risk strains HPV-16 and HPV-18 may be reimbursable.
Reimbursement criterion #8 revised to state routine cervical cancer screening is not reimbursable for individuals over 65 who are not immunocompromised, immunosuppressed, or otherwise high-risk.
Testing for low-risk HPV is not reimbursable.
For cervical cancer screening, all other technologies not discussed in the policy are not reimbursable.
Procedure code 87626 was added and code O500T was removed.
Coverage and Reimbursement Criteria
Covered screening criteria
Covered when the conditions below are met according to age and risk status:
Immunocompromised individuals
- Techniques: a) Annual cervical cytology testing for individuals of all ages; b) Co-testing (cervical cytology and high-risk HPV testing) once every 3 years for individuals 30 years of age or older.
Age 30-65
- Options: a) Conventional or liquid based Pap smear once every 3 years; b) High-risk HPV test alone once every 5 years; c) Co-testing (cytology with concurrent high-risk HPV testing) once every 5 years.
reflex HPV-16/18 genotyping
Cervical cancer screening for individuals younger than 21 years of age is generally not reimbursable. Exceptions exist only where other specific criteria in this policy apply (for example, documented history of HIV or other immunocompromising condition, prior diagnosis of cervical cancer or high-grade dysplasia, or other circumstances explicitly noted elsewhere in the reimbursement criteria). Claims for screening in individuals <21 that do not meet an exception are subject to denial.
Providers should document the clinical indication supporting any screening performed on individuals under 21 (e.g., HIV, prior high-grade lesion, prior cervical cancer) and submit that documentation with the claim to demonstrate the applicable exception. Routine screening for this age group without qualifying conditions is excluded from coverage.
Routine cervical cancer screening is not reimbursable for individuals over 65 years of age who are not considered high-risk. High-risk status includes a history of high‑grade precancerous lesion or cervical cancer, documented in‑utero diethylstilbestrol (DES) exposure, or other conditions identified in this policy. For individuals >65 who meet high‑risk criteria, screening at the frequencies described for ages 30–65 may be reimbursable.
When submitting claims for screening in individuals over 65, include documentation supporting high‑risk status when applicable. Absent evidence of high‑risk features or ongoing clinical indications, routine screening claims for members >65 are not eligible for reimbursement.
Procedure and Billing Codes
Provider Responsibilities, Billing, and Denial Risk
Claims documentation and coding
Providers must submit accurate, complete documentation and use HIPAA‑approved code sets when billing for cervical cancer screening services. Claims are subject to code‑edit protocols and clinical review; upon request, submit additional supporting documentation to avoid denials.
- Submit claims using valid code combinations from HIPAA‑approved code sets (CPT, HCPCS, ICD‑10, NDC, DRG).
- Claims are reviewed against benefit terms, provider contracts, medical policies, clinical payment and coding policies, and automated code‑edit software.
- Provide additional documentation promptly when requested to support medical necessity.
Procedure codes referenced (billing alert)
The listed procedure codes are actionable billing items but inclusion does not guarantee coverage. Review member benefit documents and clinical criteria before billing.
Provider operational note: ordering and frequency
Important provider action: follow the reimbursement frequency and population rules precisely when ordering and billing for cervical cancer screening to prevent claim denials.
- Do not reimburse routine screening for individuals under 21 years (except specified exceptions for immunocompromised) or for individuals >65 who are not high‑risk/immunocompromised.
- Follow age‑ and risk‑based frequency: e.g., Pap every 3 years for ages 21–29; for ages 30–65 follow options in policy (Pap every 3 years; hr‑HPV alone every 5 years; or co‑testing per criteria).
- Do not bill for low‑risk HPV testing or technologies not described in this policy.
Potential denial triggers
Claims may be denied for age, surgical history, or test type conflicts with the policy. Review these common denial triggers before submitting claims.
- Non‑reimbursable: screening for individuals <21 years (unless specified exception).
- Non‑reimbursable: routine screening for individuals >65 who are not high‑risk or immunocompromised.
- Non‑reimbursable: screening after total hysterectomy when there is no history of cervical cancer or pre‑cancer.
- Non‑reimbursable: low‑risk HPV testing and other technologies not addressed in this policy.
Clinical and Guideline Background
This reimbursement policy aligns coverage criteria for cervical cancer screening with major guideline bodies and clinical practice by specifying age-based intervals and separate rules for immunocompromised or otherwise high‑risk individuals. It defines covered techniques (cytology, high‑risk HPV testing, and co‑testing) and operationalizes reflex nucleic acid genotyping for HPV‑16 and HPV‑18 when pooled high‑risk HPV testing is positive.
The policy rationale balances evidence-based screening intervals (e.g., Pap every 3 years for ages 21–29; Pap, hr‑HPV alone, or co‑testing options for ages 30–65 with defined intervals) with exclusions intended to avoid low‑value or unnecessary testing — for example, routine screening under age 21 and routine screening over 65 in average‑risk individuals are not reimbursable. The policy also excludes testing for low‑risk HPV and any technologies not explicitly discussed.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.